inn

(redirected from Bortezomib)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

inn

see HOTEL.

INN. A house where a traveller is furnished with every thing he has occasion for while on his way. Bac. Ab. Inns. B; 12 Mod. 255; 3 B. & A. 283; 4 Campb. 77; 2 Chit. Rep. 484; 3 Chit. Com. Law, 365, n. 6.
     2. All travellers have a lawful right to enter an inn for the purpose of being accommodated. It has been held that an innkeeper in a town through which lines of stages pass, has no right to, exclude the driver of one of these lines from his yard and the common public rooms, where travellers are usually placed, who comes there at proper hours, and in a proper manner, to solicit passengers for his coach, and without doing any injury to the innkeeper. 8 N. H. R. 523; Hamm. N. P. 170. Vide Entry; Guest.

References in periodicals archive ?
The Ministry's approval is based on data from the phase III ALCYONE study that showed a reduction of the risk of disease progression or death by 50% in newly diagnosed ASCT ineligible multiple myeloma patients when daratumumab is combined with bortezomib, melphalan and prednisone.
The approval is based on data from the Phase III ALCYONE study that showed a reduction of the risk of disease progression or death by 50 percent in newly diagnosed ASCT ineligible multiple myeloma patients when daratumumab is combined with bortezomib, melphalan and prednisone.
* IMNOVID in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at least one prior treatment regimen including REVLIMID.
Bortezomib is a proteasome inhibitor that has been approved by the Food and Drug Administration for treatment of patients with MM.
We used low dose IVIG, Plasma exchange, Rituximab and Bortezomib to successfully desensitize and transplant three Highly HLA sensitized recipients at our center.
In general, the patients in this study tolerated bortezomib combination therapy well.
A selective proteasome inhibitor, bortezomib, has been used with encouraging results in the treatment of AL amyloidosis.
Extensive PubMed search was performed to screen the literature using the search words "bortezomib" and "pulmonary injury," "pulmonary toxicity," "lung injury," "lung toxicity," "pneumonitis," "pulmonary side effects," "lung side effects," "shortness of breath," "breathlessness," "dyspnea," "ARDS," or "respiratory failure." BLI was defined as new onset of respiratory symptoms with new radiological finding without evidence of infection and other causes of respiratory symptoms including cardiac causes and other drug-related adverse effects.
In case of bortezomib, this is usually dominantly sensory, while in case of thalidomide, it is typically a sensomotor neuropathy.
We first examined the sensitivity of two well-characterized endometrial cancer cell lines with known p53 mutational status to the proteasome inhibitor, bortezomib (Velcade[R]).
With patients over 65, the following protocols are applied in the introductory therapy: Melphalan, Thalidomide, Pronison (MPT), Melphalan, Bortezomib, Pronison (MPV), Lenalidomide-Dexasone (Rd), Bendamustine, Pronison (BP).
Bortezomib (Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, Cambridge, Massachusetts, USA) was administered in a dose of 1.3 mg/[m.sup.2] on days 1, 4, 8 and 11, and was combined with dexamethasone (VelDex) in 31 (20.9%), with cyclophosphamide (CyBorD) in 54 (36.5%) and with anthracycline (PAD) in 14 (9.5%) patients.